MicroRNA-10a-5p suppresses cancer proliferation and division in human cervical cancer by targeting BDNF

LIANCHENG ZHAI, YANLI LI, XINZHI LAN and LIANG AI

Laboratory Department, Maternal and Child Health Care Hospital of Zhengzhou, Zhengzhou, Henan 450000, P.R. China

Received May 16, 2016; Accepted March 24, 2017

DOI: 10.3892/etm.2017.5312

Abstract. The aim of the present study was to investigate the effect and mechanism of microRNA (miR)-10a-5p in human cervical cancer. The expression level of miR-10-5p in cervical cancer lines was assessed using reverse transcription-quantitative polymerase chain reaction (RT-qPCR). In cervical cancer HeLa and SiHa cells, miR-10-5p was ectopically overexpressed by lentiviral transduction. Brain-derived neurotrophic factor (BDNF) was then overexpressed in HeLa and SiHa cells to evaluate its selective effect on miR-10-5p in cervical cancer modulation. The targeting of miR-10-5p on its downstream gene, BDNF, was evaluated using RT-qPCR and western blot analysis. Cervical cancer cell viability and cell cycle was evaluated using an MTT assay and flow cytometry, respectively. The results indicated that miR-10-5p expression was significantly lower in cervical cancer cell lines compared with normal cells (P<0.05). Ectopic overexpression of miR-10-5p significantly inhibited cancer cell viability and induced cell cycle arrest in HeLa and SiHa cells (both P<0.05). miR-10-5p overexpression significantly reduced BDNF gene expression (P<0.05) and also reduced BDNF protein levels in cervical cancer cells compared with the control. In conclusion, the current study indicated that miR-10-5p is a cervical cancer suppressor, which regulates BDNF expression in cervical cancer.

Introduction

Cervical cancer is the second most commonly diagnosed cancer and the third leading cause of cancer-associated mortality among females in less developed countries (1). There are 527,600 new cervical cancer cases each year, accounting for ~38% of the global incidence (4). Cervical cancer is more prevalent in developing countries, where >85% of cases occur (3). China has the highest incidence of cervical cancer worldwide with ~140,000 new cervical cancer cases each year, accounting for ~38% of the global incidence (4).

MicroRNAs (miRNAs or miRs) are a type of short length, highly conservative, non-coding RNA, which are able to affect gene expression by binding to the 3′-untranslated region of target genes (5). miRNAs may act as either oncogenic factors or tumor suppressors in various types of cancer (6). In human cervical cancer, the miR-27b cluster was previously found to serve an oncogenic role in cervical cancer by promoting proliferation and was upregulated by papillomavirus 16 E7 (7). Conversely, several miRs, including miR-646, miR-141 and miR-205, were observed to be downregulated in cervical cancer (8-10). Various miRs act as tumor suppressors, including the miR-10 family, which suppresses cancer cell proliferation and promotes cancer cell apoptosis (11,12). However, there are limited studies focusing on the relationship between miR-10-5p, another member of the miR-10 family, and cervical carcinoma.

Brain-derived neurotrophic factor (BDNF) is a transcription factor that serves a key function in the process of neural differentiation (13). Previous studies have suggested that BDNF is also a key regulator of cancer (14-16). However, little is known about the molecular pathways of BDNF in cervical cancer.

The current study aimed to investigate the association between miR-10-5p and the biological characteristics of cervical cancer cell lines. The results indicated that upregulation of miR-10-5p has inhibitory effects on cervical cancer. In addition, it was demonstrated that the pro-oncogenic gene BDNF was suppressed by upregulation of miR-10-5p in cervical cancer cells.

Materials and methods

Cervical cancer cell culture. Five cervical cancer cell lines were studied: SiHa, HeLa, CaSki, C4-I and C-33a. These cell lines were all obtained from the American Type Culture Collection (Manassas, VA, USA). Normal cervical epithelial cells from the human uterus were purchased from ScienCell Research Laboratories (San Diego, CA, USA). All cells were cultured in Dulbecco’s modified Eagle’s medium (DMEM), high-glucose, supplemented with 10% fetal calf serum (both from Invitrogen; Thermo Fisher Scientific, Inc., Waltham,
MA in a tissue culture incubator at 37°C with 5% CO₂ until 90% confluence was reached. All specimens were immediately snap-frozen in liquid nitrogen and stored at -80°C for subsequent experimentation.

**RNA extraction and reverse transcription-quantitative polymerase chain reaction (RT-qPCR).** Total RNA (2 μg) from cervical cell lines was extracted using TRIzol reagent (Invitrogen; Thermo Fisher Scientific, Inc.). A SuperScript™ one-step RT-PCR kit (Invitrogen; Thermo Fisher Scientific, Inc.) was used to perform RT-qPCR. For reverse transcription, the first strand was synthesized using oligo (dT) primers, DEPC-treated water, reverse transcriptase buffer, dNTPs mixture, RNase inhibitor and reverse transcriptase. The reaction steps were set by incubating at 42°C for 1 h followed by a 10 min incubation at 92°C to denature the reverse transcriptase (Invitrogen; Thermo Fisher Scientific, Inc.) and separate complementary strands. cDNA was subsequently used to perform PCR using β-actin as an internal control. The sequences of the primers used were as follows: miR-10-5p, 5'-UACCCUGUGAGUUCCGAUUUGU-3'; BDNF forward, 5'-CTACGAGACCAATGCACATCC-3' and reverse, 5'-AAT CGCCAGCCATTTCTCTTT-3'; and β-actin forward, 5'-CTC CATCCAGGGCCTG-3' and reverse, 5'-GCTGTCACCTTC ACCGGTCCC-3'. qPCR was performed in a total final 20 μl volume consisting of 0.5 μl cDNA, 1 μl Taq polymerase, 1.1 μl TaqMan probe, 0.4 μl, 10 nM dNTPs, 2 μl 10x PCR buffer and 15 μl DEPC-treated water. The thermocycling conditions of PCR were performed as follows: 95°C for 10 min; 65°C for 45 sec; 72°C for 1 min, for 35 cycles. All reactions including control groups were performed in triplicate. The results were analyzed by 2-ΔΔCt method (17).

**Lentivirus production.** In the present study, human miR-10-5p was transfected into lentivirus (lentimiR10a-5p) and empty lentivirus lenti-miRNA control (mi-RC) was used as a negative control. All products were purchased from SunBio Biotech, Co., Ltd. (Beijing, China). Lenti-miR10a-5p or lenti-miRC [100 nM; GenScript (Nanjing) Co., Ltd., Nanjing, China] were then transduced into HeLa and SiHa cells using Lipofectamine 2000 (Biomics Biotechnologies Co., Ltd., Nantong, China) following a previously published protocol (18).

**Cervical cancer cell viability assay.** The viability of HeLa and SiHa cells was evaluated using an MTT assay (Invitrogen; Thermo Fisher Scientific, Inc.), according to the manufacturer's protocol. In a 96-well plate (5,000 cells/well), lentivirus-transduced HeLa and SiHa cells were maintained for 5 days at 20°C. All cervical cancer cell lines were incubated with a volume fraction of 10% FBS DMEM culture liquid at 37°C and 5% CO₂. Cells were collected from the plates using trypsin and washed with PBS. Cell viability was measured using an MTT assay kit (Beyotime Institute of Biotechnology, Haimen, China) and the optical density at a wavelength of 490 nm was detected using a microplate reader (Multiskan MK3; Thermo Fisher Scientific, Inc.).

**Western blot analysis.** For western blot analysis, cells from the control and miR-10-5p groups were lysed with lysis buffer (Beyotime Institute of Biotechnology) according to the manufacturer's protocol. Proteins were isolated by centrifugation at 13,000 x g at 5°C for 5 min. A BCA kit (Shanghai Qcbio Science and Technologies Co., Ltd., Shanghai, China) was utilized for protein quantification according to the manufacturer's protocol. A total of 50 μg protein was then loaded on to each lane for SDS-PAGE. The concentrations of stacking and resolving gel were 5 and 15% respectively. Following SDS-PAGE, proteins were transferred to PVDF membranes [cat no. L03014; GenScript (Nanjing) Co., Ltd., Nanjing, China] and the results were analyzed using Multicycle AV 1.0 software (Phoenix Flow Systems, San Diego, CA, USA).

**Figure 1.** miR-10-5p gene expression in cervical cancer cell lines and normal cervical cells. *p<0.05 vs. normal cells. miR-10-5p, microRNA-10a-5p.
EXPERIMENTAL AND THERAPEUTIC MEDICINE 14: 6147-6151, 2017

**Statistical analysis.** Data are presented as the mean ± standard deviation. Comparisons between two groups were evaluated using the two-tailed Student's t-test with SPSS 19.0 software (SPSS Inc., Chicago, IL, USA). P<0.05 was considered to indicate a statistically significant difference.

**Results**

miR-10-5p expression in cervical cancer cells and normal cervical cells. miR-10-5p expression was evaluated in five cervical cancer cell lines (SiHa, HeLa, CaSki, C4-1 and C-33a) and normal cervical cells using RT-qPCR. It was demonstrated
that miR-10-5p expression was significantly lower in all cervical cancer cell lines compared with normal cervical cells (P<0.05; Fig. 1).

**Effect of miR-10-5p on the viability and cell cycle of cervical cancer cells.** As miR-10-5p was significantly downregulated in cervical cancer cells compared with normal cervical cells, it was hypothesized that overexpression of miR-10-5p may have an inhibitory effect on the viability of cervical cancer cells. Therefore, miR-10-5p was upregulated in HeLa and SiHa cells using lentiviral miR-10-5p. Compared with lentiviral miRC, lentiviral miR-10-5p caused a significant increase in the expression of miR-10-5p in both HeLa and SiHa cells (P<0.05; Fig. 2A).

An MTT assay indicated that overexpression of miR-10-5p was able to significantly reduce cell viability at day 4 and 5 compared with the control in HeLa and SiHa cells (P<0.05; Fig. 2B). To better understand its inhibitory mechanism, the effect of miR-10-5p overexpression on cervical cancer cell cycle regulation was evaluated by flow cytometry. The results indicated that miR-10-5p overexpression suppressed cervical cancer cell cycle progression, as significantly more HeLa and SiHa cells were arrested at G1 stage in miR-10-5p-upregulated cells compared with the control (P<0.05; Fig. 2C).

**BDNF mRNA and protein expression in cells.** BDNF is a target gene of miR-10-5p (19). The current study aimed to investigate the association between BDNF and miR-10-5p in two different cervical cancer cell lines (HeLa and SiHa). BDNF mRNA expression was evaluated using RT-qPCR and BDNF protein expression was assessed by western blot analysis. The results indicated that overexpression of miR-10-5p significantly inhibited BDNF mRNA expression in HeLa (P<0.05; Fig. 3A) and SiHa cells (P<0.05; Fig. 3B) compared with the control. miR-10-5p overexpression also suppressed BDNF protein expression in HeLa and SiHa cells compared with the control (Fig. 3C).

**Discussion**

miRNA has previously been identified as an important factor in cell proliferation, division, metastasis or apoptosis in cervical cancer (20). In the present study, it was demonstrated that miR-10-5p was significantly downregulated in cervical cancer compared with normal cervical cells. A previous study reported that miR-10-5p was downregulated in chronic laryngeal epithelial premalignant lesions (21).

The current study indicated that the overexpression of mir-10a-5p reduced cell viability and delayed cell cycle progression in cervical cancer cells. In laryngeal epithelial premalignant lesions, miR-10-5p induced cancer cell apoptosis (21). The current findings are consistent with the aberrant downregulation of miR-10-5p in cancer and support the proposal that miR-10-5p has a tumor suppressor role in various types of cancer.

In the present study, it was identified that BDNF was a target gene of miR-10-5p in cervical cancer cells. In previous studies, it was proposed that miR-10a-10b targeted cell apoptosis or cell division related genes, such as MIB1 LPO, to induce apoptosis and cell cycle arrest (22,23). Therefore, the current study aimed to explore the relationship between miR-10a-5p and BDNF in the development of cancer. In some types of cancer, BDNF may act as an oncogene. Suppressing BDNF expression has been reported to inhibit cancer proliferation (14,24).

The current results indicated that upregulation of miR-10-5p expression decreased viability and inhibited cell cycle progression in cervical cancer cell lines. It was also indicated that BDNF was the target gene of miR-10-5p, and therefore miR-10-5p may be a key cervical cancer regulator. These data may help to identify novel molecular pathways to provide targeted gene therapy for cervical cancer patients.

**References**


